Absstract of: CN121891418A
The invention relates to the field of microorganisms, and discloses application and a method of aspergillus cristatus in preparation of a medicine for treating and/or preventing bacterial infection, and the preservation number of the aspergillus cristatus is CGMCC No.41727. The aspergillus cristatus provided by the invention has an inhibition effect on streptococcus mutans, escherichia coli, staphylococcus aureus and salmonella typhimurium, can secrete various active enzymes, and can relieve the symptoms of bacterial infection, including inhibition of expression of proinflammatory factors, promotion of expression of anti-inflammatory factors and reduction of the number of neutrophils; the aspergillus cristatus provided by the invention can also relieve the symptoms of colitis. The aspergillus cristatus provided by the invention has an application prospect in preparation of drugs for treating and/or preventing bacterial infection.
Absstract of: CN121896139A
本发明属于兽医生物制品领域,具体涉及一株驴源马流产沙门菌spiC基因缺失株YZUSAL01ΔspiC及其构建方法和应用。本发明的基因缺失株已保藏于中国典型培养物保藏中心,保藏编号为CCTCC NO:M 20252392。该缺失株是利用λ‑Red同源重组技术,将马流产沙门菌的spiC基因敲除后获得的。本发明制备的基因缺失株毒力显著下降,具有良好的安全性。攻毒保护试验表明该菌株对小鼠的攻毒免疫保护效果良好,可诱导高效的体液免疫。本发明为预防马流产沙门菌感染提供了安全、保护效力高的减毒活疫苗奠定基础。
Absstract of: CN121873260A
The invention relates to an antibacterial peptide, the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 2, or a polypeptide which is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence as shown in SEQ ID NO: 2 and has antibacterial activity for escherichia coli, staphylococcus aureus and salmonella. The antibacterial peptide disclosed by the invention has a remarkable inhibition effect on main pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus and drug-resistant strains thereof in animal husbandry, and is wide in antibacterial spectrum and high in activity; the feed additive has excellent thermal stability and acid resistance, can tolerate feed granulation high temperature and gastric acid degradation, and ensures effective effects of intestinal tracts; the hemolytic activity is low, and the biological safety is high; the expression quantity of a pichia pastoris fermentation tank is greatly improved, the production cost is remarkably reduced, and the economical requirement of large-scale feed addition is met.
Absstract of: CN121868347A
The invention belongs to the technical field of biology, discloses a culture supernatant of Brawler's bacteria and application, a preparation method and a medicine of a metabolite of the culture supernatant, and discloses application of the culture supernatant of the Brawler's bacteria to preparation of an anti-inflammatory medicine. According to the application, a chicken infected with salmonella is drenched with a Brawler's metabolite in advance, and tests show that the Brawler's metabolite not only can reduce the death rate of the chicken infected with salmonella, but also has obvious inhibition capability on inflammations of multiple organs of the whole body including intestinal tracts, spleen and the like.
Absstract of: CN121874062A
The invention belongs to the technical field of microorganisms, and particularly relates to lactic acid bacteria and application thereof. The bacterial strain is Ligilobacillus sativus SunLab-GHL01 (L.sativus GHL01 for short), is separated from lungs of high-production-performance Ailijiai broiler chickens and is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number of the bacterial strain is CCTCC NO: M 20251725. The invention further discloses a preparation method of the high-production-performance Ailijiai broiler chicken with high-production-performance Ailijiai broiler chicken with high-production-performance Ailijiai broiler chicken with high-production-performance Ailijiai broiler chicken. Through morphology, physiology and biochemistry, 16S rRNA sequence identification and whole genome sequencing analysis, the taxonomic status and functional characteristics of the 16S rRNA are defined. The strain has good acid resistance, cholate resistance and acid production capacity, has broad-spectrum antibacterial activity, and can effectively inhibit pathogenic bacteria such as escherichia coli, pathogenic escherichia coli, salmonella, staphylococcus aureus and pseudomonas aeruginosa. Animal experiments show that the poultry feed conversion rate and the anti-stress capability can be remarkably improved by atomizing the strain. The strain and the application thereof can be used for improving the health condition and the production performa
Absstract of: CN121874020A
The invention provides lactobacillus reuteri MRL1103 and application thereof, and relates to the technical field of microorganisms and mercury adsorption, the preservation number of the lactobacillus reuteri MRL1103 with a mercury adsorption function is CGMCC NO.28840, the lactobacillus reuteri MRL1103 is separated from fresh chicken manure, the lactobacillus reuteri MRL1103 can tolerate a mercury solution with the concentration as high as 100 mg/L, and under the conditions that the pH is 5 and the concentration of the mercury solution is 5 mg/L, the concentration of the mercury solution can reach 100 mg/L, and the concentration of the mercury solution can reach 100 mg/L; the adsorption rate of the lactobacillus reuteri MRL1103 on mercury in a mercury solution reaches 95% or above, and the lactobacillus reuteri MRL1103 has an inhibition effect on escherichia coli, staphylococcus aureus, salmonella enteritidis, salmonella pullorum or salmonella typhimurium. The lactobacillus reuteri MRL1103 can be used for removing a mercury metal element in a matrix, and the matrix can be mercury-containing soil, a feed or a culture medium.
Nº publicación: WO2026080385A1 16/04/2026
Applicant:
UNIV COLORADO REGENTS [US]
BENAROYA RES INSTITUTE AT VIRGINIA MASON [US]
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON
Absstract of: WO2026080385A1
Methods for the detection of subjects at risk of developing rheumatoid arthritis, and subjects having early rheumatoid arthritis thus allowing for early intervention. Compositions for inducing immune tolerance in a subject thus treating or slowing progression of RA. Kits useful in the diagnosis of RA.